Patents by Inventor Paul Ridker

Paul Ridker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF CANAKINUMAB
    Publication number: 20240043525
    Abstract: The present invention relates to canakinumab for use in reducing the risk of or preventing recurrent cardiovascular (CV) events in a patient with elevated hsCRP that has suffered myocardial infarction (MI).
    Type: Application
    Filed: March 21, 2023
    Publication date: February 8, 2024
    Inventors: Georgina BERMANN, Peter LIBBY, Paul RIDKER, Tom THUREN
  • IL-1BETA BINDING ANTIBODIES FOR USE IN TREATING CANCER
    Publication number: 20230220063
    Abstract: Use of an IL-1? binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis.
    Type: Application
    Filed: June 22, 2018
    Publication date: July 13, 2023
    Inventors: Monica LIGUEROS-SAYLAN, Patrice MATCHABA, Tom THUREN, Paul RIDKER, Peter LIBBY, Penelope OTTEWELL, Yang Yi LAU, Margaret DUGAN
  • USE OF IL-1BETA BINDING ANTIBODIES
    Publication number: 20220389090
    Abstract: Use of an IL-1? binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis.
    Type: Application
    Filed: January 10, 2022
    Publication date: December 8, 2022
    Inventors: Margaret Han DUGAN, Yi Yang LAU, Peter LIBBY, Monica LIGUEROS-SAYLAN, Patrice Tinaye MATCHABA, Penelope OTTEWELL, Paul RIDKER, Tom THUREN
  • USE OF CANAKINUMAB
    Publication number: 20200239564
    Abstract: The present invention relates to canakinumab for use in reducing the risk of or preventing recurrent cardiovascular (CV) events in a patient with elevated hsCRP that has suffered myocardial infarction (MI).
    Type: Application
    Filed: August 24, 2018
    Publication date: July 30, 2020
    Inventors: Paul RIDKER, Tom THUREN, Georgina BERMANN, Peter LIBBY
  • USE OF IL-1beta BINDING ANTIBODIES
    Publication number: 20190048072
    Abstract: Use of an IL-1? binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis.
    Type: Application
    Filed: May 3, 2018
    Publication date: February 14, 2019
    Inventors: Monica Ligueros-Saylan, Patrice Matchaba, Tom Thuren, Paul Ridker, Peter Libby, Penelope OTTEWELL, Yi Yang LAU, Margaret DUGAN
  • POLYMORPHISM IN THE APO(A) GENE PREDICT RESPONSIVENESS TO ACETYLSALICYLIC ACID TREATMENT
    Publication number: 20110206667
    Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Application
    Filed: April 19, 2011
    Publication date: August 25, 2011
    Applicants: The Brigham and Women's Hospital, Inc., Applera Corporation
    Inventors: Paul Ridker, Daniel Chasman, Dov Shiffman
  • Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
    Patent number: 7964614
    Abstract: The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: June 21, 2011
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Paul Ridker, Charles H. Hennekens
  • Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment
    Patent number: 7943317
    Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: May 17, 2011
    Assignees: The Brigham and Women's Hospital, Inc., Applera Corporation
    Inventors: Paul Ridker, Daniel Chasman, Dov Shiffman
  • POLYMORPHISM IN THE APO(A) GENE PREDICT RESPONSIVENESS TO ACETYLSALICYLIC ACID TREATMENT (RIDKER)
    Publication number: 20090004187
    Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Application
    Filed: May 9, 2008
    Publication date: January 1, 2009
    Inventors: Paul Ridker, Daniel Chasman, Dov Shiffman
  • Soluble CD40L (CD 154) as a prognostic marker of atherosclerotic diseases
    Publication number: 20080058360
    Abstract: This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment are also described.
    Type: Application
    Filed: March 12, 2007
    Publication date: March 6, 2008
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Uwe Schonbeck, Paul Ridker, Peter Libby
  • Relevance of achieved levels of markers of systemic inflammation following treatment
    Publication number: 20070292960
    Abstract: The invention involves, inter alia, the use of markers of systemic inflammation to determine whether or not an individual undergoing treatment with a cardiovascular agent to reduce the risk of a future cardiovascular event will benefit from continued treatment with the cardiovascular agent. Further, this invention describes the use of markers of systemic inflammation to evaluate the efficacy of treatment and to assist physicians in deciding on the course of a treatment in an individual at risk of future cardiovascular events.
    Type: Application
    Filed: October 6, 2005
    Publication date: December 20, 2007
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventor: Paul Ridker
  • Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases
    Patent number: 7189518
    Abstract: This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment also are described.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: March 13, 2007
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Uwe Schönbeck, Paul Ridker, Peter Libby
  • Relevance of achieved levels of markers of systemic inflammation following treatment
    Publication number: 20060115903
    Abstract: The invention involves, inter alia, the use of markers of systemic inflammation to determine whether or not an individual undergoing treatment with a cardiovascular agent to reduce the risk of a future cardiovascular event will benefit from continued treatment with the cardiovascular agent. Further, this invention describes the use of markers of systemic inflammation to evaluate the efficacy of treatment and to assist physicians in deciding on the course of a treatment in an individual at risk of future cardiovascular events.
    Type: Application
    Filed: October 6, 2005
    Publication date: June 1, 2006
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventor: Paul Ridker
  • Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
    Publication number: 20060104941
    Abstract: The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.
    Type: Application
    Filed: June 22, 2005
    Publication date: May 18, 2006
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Paul Ridker, Charles Hennekens
  • Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
    Patent number: 7030152
    Abstract: The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: April 18, 2006
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Paul Ridker, Charles H. Hennekens
  • Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases
    Publication number: 20030152566
    Abstract: This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment also are described.
    Type: Application
    Filed: November 5, 2002
    Publication date: August 14, 2003
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Uwe Schonbeck, Paul Ridker, Peter Libby
  • Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
    Patent number: 6040147
    Abstract: The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.
    Type: Grant
    Filed: April 2, 1998
    Date of Patent: March 21, 2000
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Paul Ridker, Charles H. Hennekens